This may account for the observation that a portion of MM patients do not respond to antibody therapy and nearly all patients will ultimately become refractory to treatment.70,71 Targeting CD38 enzymatic activity in the TME presents a potential new strategy for combating the immunosuppressive effects that contribute to treatment resistance to antibody therapy in high-risk NB. This evidence concerns the gene CD38 and Miyoshi myopathy.